TRANSCODE THERAPEUTICS INC

Historical 13F Holders

Symbol
RNAZ
CUSIP
89357L501
All holders as of
Q2 2026
Type
Equity
Class
COM NEW 2025
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 89357L501 since 12/18/2024, newest first.

Filer % of Class Filed
CK Life Sciences Intl (Holdings) Inc 13D/A Amendment 5
83.9% 8/3/2026
Event 8/3/2026
Unleash Immuno Oncolytics, Inc. 13G 9.9% 7/28/2026
Event 7/23/2026
Elena Rosa Braci 13G 6.2% 7/28/2026
Event 7/23/2026
Daniel Eduardo Katzman 13G 5.2% 7/28/2026
Event 7/23/2026
CK Life Sciences Intl (Holdings) Inc 13D/A Amendment 4
83.9% 7/27/2026
Event 7/27/2026
CK Life Sciences Intl (Holdings) Inc 13D/A Amendment 3
9.9% 7/23/2026
Event 7/23/2026
CK Life Sciences Intl (Holdings) Inc 13D/A Amendment 2
8.8% 7/17/2026
Event 7/17/2026
YA II PN, Ltd. 13G
9.9% 4/20/2026
Event 4/15/2026
Sabby Management, LLC 13G/A Amendment 1
4.9% 1/7/2026
Event 12/31/2025
Goldman Sachs Group Inc 13G/A Amendment 1
0% 11/10/2025
Event 9/30/2025
CK Life Sciences Intl (Holdings) Inc 13D/A Amendment 1
9.1% 10/28/2025
Event 10/27/2025
CK Life Sciences Intl (Holdings) Inc 13D
9.1% 10/16/2025
Event 10/8/2025
Goldman Sachs Group Inc 13G
5.9% 8/14/2025
Event 6/30/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 8 33.5 k $208 k
2026 Q1 8 30.9 k $266 k
2025 Q4 6 3.88 k $26.4 k
2025 Q3 8 14.4 k $155 k
2025 Q2 11 30.4 k $237 k